SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Synthetic Blood International, Inc. (SYBD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Terry Vellequette who wrote (16)3/19/1999 2:24:00 PM
From: Micro-Selector  Read Replies (1) of 91
 
Clinical research process varies widely. For detailed information, best source of official regulatory information would be:

fda.gov

However, the FDA has instituted a "fast-track" approval process for certain drugs and devices (based on need in the marketplace -- for example, many HIV treatments qualify for faster approval process). I do not know if SYBD's patented products will qualify.

My current enthusiasm stems from the fact that the products are finally patented (the glucose biosensor patent nearly in the bag) and ready for the clinical research stage. If the products show promise during the beginning stages of the clinical research phase and catch the attention of a major biotech manufacturer, SYBD could end up getting the necessary funding for the entire clinical research process, which could greatly increase their chance of building a market for the products by the time of approval.

For example, CLTR has been developing its breakthrough treatment for lymphoma for about 10 years now (which has been very costly). Because of the promise of the product, however, it has had no problem receiving government and private funding for the clinical trials.

I hope this helps. I have some experience in the clinical research field, but am certainly no expert.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News